FDA, AI, and the Future of Clinical Trials

Why the industry is moving from AI experimentation to AI governance 

For the past several years, AI in clinical trials was mostly associated with operational efficiency. The conversation focused on faster recruitment, better analytics, automated workflows, reduced administrative burden, and accelerated study execution. 

But over the past month, the FDA started signaling something much bigger. The agency is no longer treating AI simply as a useful tool around clinical trials. Instead, it is beginning to position AI as part of the clinical development infrastructure itself. And that may fundamentally change how future clinical trials are conducted. 

The FDA Is Testing Real Time Clinical Trials 

The clearest signal came when the FDA announced two proof of concept studies designed to test what the agency calls “real time clinical trials.” The first study involves AstraZeneca and its Phase II TrAVeRse trial in mantle cell lymphoma, while the second involves Amgen and its STREAM-SCLC study in small cell lung cancer. 

The goal is to reduce the long delays that often exist between what happens at clinical sites, what sponsors analyze, and what regulators eventually review. Traditionally, regulators receive information after long reporting cycles and multiple layers of data processing. The FDA is now exploring whether AI and advanced data systems can help important clinical trial signals become visible much earlier during study execution. 

The initiative focuses on areas such as: 

• safety signal detection
  • dose optimization
  • recruitment analysis 
  • operational acceleration 
  • near real time trial oversight 

Importantly, the FDA is not receiving raw patient records. Sponsors continue holding patient level data, while the agency receives aggregated signals such as safety trends, response patterns, and operational insights. 

The FDA also confirmed that it had already received and validated signals from AstraZeneca’s study through, suggesting the initiative has already moved beyond theoretical planning. 

The FDA also made clear that this initiative is not intended to replace human reviewers or formal regulatory interactions. Instead, the goal is to improve visibility and reduce operational lag within clinical development. 

At the same time, the FDA announced plans for a broader AI enabled pilot program expected later this summer, which according to reports may eventually involve several additional companies. 

The Bigger Story Is Governance

The most important part of the FDA’s recent AI initiatives may not be the promise of faster clinical trials, but the growing focus on trust, oversight, and accountability. 

In recent public discussions, the FDA focused heavily on: 
• decision quality 
• data integrity 
• model reliability 
• transparency and explainability 
• model drift and bias 
• privacy and fairness 

The FDA also referenced the NIST AI Risk Management Framework in its recent discussions around AI enabled clinical trial optimization, reinforcing the agency’s growing focus on governance, oversight, and trust around AI systems used in regulated clinical development. 

The agency is also putting greater emphasis on validation standards, lifecycle monitoring, risk based oversight, and human accountability around AI generated outputs, as outlined in the FDA’s recent Request for Information on AI-enabled clinical trial optimization. 

This matters because AI in clinical trials is starting to move beyond innovation and automation. It is becoming part of the broader regulatory infrastructure surrounding drug development. 

FDA Is Also Building Its Own Internal AI Systems 

Another important signal came from the FDA’s own internal AI rollout. The agency recently introduced expanded internal systems called Elsa 4.0 and HALO as part of a broader modernization initiative. What stood out was not futuristic automation claims, but the emphasis on governance controls. 

The FDA specifically highlighted: 
• secure infrastructure 
• restrictions on training models using industry submitted data 
• human experts validating outputs and analytic processes 

The agency’s updated AI materials also emphasized coordination through the CDER AI Council and expanded formal pathways for sponsors to discuss AI driven approaches in clinical trials, digital health technologies, model informed drug development, and real world evidence. 

Together, these developments suggest the FDA is trying to normalize a governance framework around AI internally before expecting industry participants to follow similar standards. 

Why China Is Part of the Conversation 

Another reason these developments matter is global competition. 

FDA leadership has openly linked AI modernization and faster clinical development timelines to competition with China, which has rapidly expanded its biotech ecosystem and early phase clinical trial infrastructure over the past several years. 

China has spent years modernizing regulatory timelines, trial approval systems, data oversight frameworks, and biotech investment infrastructure. At the same time, global pharmaceutical companies are increasingly turning toward Chinese biotech partnerships and innovation ecosystems as the country continues strengthening its role in global drug development. 

As a result, AI in clinical trials is becoming more than a technology discussion. It is increasingly tied to questions of speed, regulatory modernization, capital allocation, and long term competitiveness within the global clinical research landscape. 

The Industry Is Entering a New Phase 

The past few years were mostly about AI hype and experimentation. The next phase may be about governance, accountability, and regulatory trust. And the organizations that succeed may not necessarily be those using the most AI. They may be the ones most capable of integrating AI into clinical development in a way that regulators can confidently evaluate, validate, and trust. 

That challenge is becoming even more important as clinical trials themselves grow increasingly complex, data intensive, and operationally demanding. As we recently explored in our analysis of today’s clinical research landscape, the industry is no longer limited by innovation alone. More and more, success depends on the ability to execute clinical trials efficiently, consistently, and at scale within real world conditions.